|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To this end, we developed a deep learning-based cognitive signature of FDG brain PET adaptable for Parkinson's disease (PD) as well as Alzheimer's disease (AD).
|
31768599 |
2020 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction: Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.
|
30883613 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of a reduced acquisition time for <sup>18</sup>F-FDG PET studies of Alzheimer dementia (AD) and frontotemporal dementia (FTD) to derive a limit for reductions of acquisition time (improving patient compliance) and administered activity (lowering the radiation dose) with uncompromised diagnostic outcome.
|
31028167 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only a limited number of studies using <sup>18</sup>F-FDG-PET in AD mice were carried out so far showing contradictory findings in cerebral FDG uptake.
|
31058151 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The model was applied to FDG PET data of Alzheimer's disease (AD) and mild cognitive impairment (MCI) and clinical routine FDG PET data for assessing behavioral abnormality and seizures.
|
31003928 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
the evaluation is done on ADNI dataset.The proposed method outperforms other state-of-the-art <sup>18</sup>F-FDG PET-based algorithms for AD vs. NC with an accuracy, a sensitivity and a specificity values of 93.65%, 91.22% and 96.25%, respectively.
|
31430595 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b><sup>18</sup>F-FDG PET scans of 544 MCI patients were obtained from the Alzheimer Disease Neuroimaging Initiative database and analyzed.
|
30389825 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, <sup>18</sup>F-FDG PET and clinical assessments were collected in a cohort of 422 individuals [including 130 with AD, 130 with MCI, and 162 healthy controls (HCs)] from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and 44 individuals (including 22 with AD, and 22 HCs) from Huashan Hospital, Shanghai, China.
|
30956687 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metabolic Brain Network Analysis of FDG-PET in Alzheimer's Disease Using Kernel-Based Persistent Features.
|
31234358 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review aims to help readers understand the role of <sup>18</sup>F-FDG PET/CT imaging in the investigation of cognitive impairment and how the advent of amyloid PET/CT imaging may hold the key to radically changing management of the most common form of dementia - Alzheimer's disease.
|
30982329 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed ninety-six subjects (27 cognitively normal, 49 mild cognitive impairment, and 20 AD dementia) who underwent [<sup>18</sup>F]FDG and [<sup>18</sup>F]Florbetapir positron emission tomography (PET) as well as magnetic resonance imaging (MRI) with diffusion tensor imaging.
|
30414086 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET, the early phases and the delivery rate of <sup>18</sup>F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against <sup>15</sup>O-H<sub>2</sub>O PET.
|
31405824 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
SNAP subjects show milder impairment of brain [<sup>18</sup>F] FDG uptake as compared to AD.
|
31201430 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 38 patients with mild-to-moderate AD (mean age 67 ± 7 years, mean MMSE score 24 ± 4, mean years of education 14 ± 4; 20 men, 18 women) in whom a [<sup>18</sup>F]AV-1451 scan (a measure of tau pathology) and an [<sup>18</sup>F]FDG scan (a measure of neuronal function) were available.
|
31183635 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Experiments on Alzheimer's Disease Neuroimaging Initiative database show that the proposed method outperforms most FDG-PET-based classification algorithms, especially for classifying progressive MCI (pMCI) from stable MCI (sMCI).
|
30028716 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyloid PET provides significant incremental diagnostic value beyond clinical and [<sup>18</sup>F]FDG PET diagnoses of AD.
|
30094462 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Globally normalized 18F-FDG-PET values and levels of NFL and tau were obtained from 149 patients with mild cognitive impairment (MCI) from the baseline cohort of the Alzheimer's Disease Neuroimaging Initiative database.
|
31305887 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reduced <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism was recognized as a biomarker of neurodegeneration in the recently proposed ATN framework for Alzheimer's disease (AD) biological definition.
|
31253185 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of genotype and age on cerebral [<sup>18</sup>F]FDG uptake varies between transgenic APP<sub>Swe</sub>-PS1<sub>dE9</sub> and Tg2576 mouse models of Alzheimer's disease.
|
30952945 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer's disease.
|
31672138 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the sensitivity of the ratio mapping, we also utilized well-validated AD imaging biomarkers as the reference, including gray matter volume and Fludeoxyglucose PET (FDG-PET).
|
31551678 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hyperglycemia affects FDG uptake in the brain, potentially emulating Alzheimer's disease in normal individuals.
|
30784923 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The use of graph theory for the quantification of [<sup>18</sup>F]FDG brain PET covariance, including the definition of an entropy metric, proved to be particularly relevant for Alzheimer's disease, showing an association with the progression of the pathology.
|
30792460 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tau pathology overlapped with areas of hypometabolism on FDG PET in the brains of AD patients.
|
31584490 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NL-ENIGMA study explored the effect of Souvenaid on synapse function in early AD by assessing cerebral glucose metabolism (CMRglc) with <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography (PET).
|
31650005 |
2019 |